The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model.
Authors
Gibbons, AileenPadilla-Carlin, Danielle
Kelly, Ciara
Hickey, Anthony J
Taggart, Clifford
McElvaney, Noel G
Cryan, Sally-Ann
Affiliation
School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland.Issue Date
2011-09MeSH
Administration, InhalationAnimals
Anti-Asthmatic Agents
Asthma
Biological Transport
Cell Line
Cell Membrane Permeability
Disease Models, Animal
Drug Compounding
Drug Delivery Systems
Drug Stability
Electric Impedance
Enzyme-Linked Immunosorbent Assay
Guinea Pigs
Humans
Liposomes
Male
Respiratory Mucosa
Secretory Leukocyte Peptidase Inhibitor
Metadata
Show full item recordCitation
The effect of liposome encapsulation on the pharmacokinetics of recombinant secretory leukocyte protease inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model. 2011, 28 (9):2233-45 Pharm. Res.Journal
Pharmaceutical researchDOI
10.1007/s11095-011-0454-1PubMed ID
21647791Abstract
Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.Item Type
ArticleLanguage
enISSN
1573-904Xae974a485f413a2113503eed53cd6c53
10.1007/s11095-011-0454-1
Scopus Count
Collections
Related articles
- A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation.
- Authors: Gibbons A, McElvaney NG, Cryan SA
- Issue date: 2010 Sep
- Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation.
- Authors: Gibbons AM, McElvaney NG, Taggart CC, Cryan SA
- Issue date: 2009 Sep
- Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.
- Authors: Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, Yang Z
- Issue date: 2012
- Recombinant human secretory leukocyte-protease inhibitor: in vitro properties, and amelioration of human neutrophil elastase-induced emphysema and secretory cell metaplasia in the hamster.
- Authors: Lucey EC, Stone PJ, Ciccolella DE, Breuer R, Christensen TG, Thompson RC, Snider GL
- Issue date: 1990 Feb
- Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis.
- Authors: McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG
- Issue date: 1993 Oct